These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies. Andrès E; Villalba NL; Zulfiqar AA; Serraj K; Mourot-Cottet R; Gottenberg AJ J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31480527 [TBL] [Abstract][Full Text] [Related]
4. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. Weycker D; Barron R; Kartashov A; Legg J; Lyman GH J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496 [TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Lynn JJ; Chen KF; Weng YM; Chiu TF Hematol Oncol; 2013 Dec; 31(4):189-96. PubMed ID: 23303687 [TBL] [Abstract][Full Text] [Related]
9. [Management of febrile neutropenia in cancer patients]. Freres P; Gonne E; Collignon J; Giot JB; Gennigens C; Jerusalem G Rev Med Liege; 2015 Apr; 70(4):195-200. PubMed ID: 26054171 [TBL] [Abstract][Full Text] [Related]
10. History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort. Andrès E; Mourot-Cottet R; Maloisel F; Vogel T; Tebacher M; Gottenberg JE Eur J Intern Med; 2017 Dec; 46():e13-e14. PubMed ID: 28823525 [No Abstract] [Full Text] [Related]
12. Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data. Badawy SM; Palmblad J; Tricta F; Toiber Temin N; Fradette C; Lin L; Rozova A; Sheth S Blood Adv; 2024 Apr; ():. PubMed ID: 38640437 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. van der Galiën HT; Loeffen EAH; Miedema KGE; Tissing WJE Support Care Cancer; 2018 Nov; 26(11):3819-3826. PubMed ID: 29777383 [TBL] [Abstract][Full Text] [Related]
14. Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous. Rattay B; Benndorf RA Front Pharmacol; 2021; 12():727717. PubMed ID: 34483939 [TBL] [Abstract][Full Text] [Related]
15. FACTORS ASSOCIATED WITH TREATMENT OUTCOME OF PEDIATRIC CANCERPATIENTS ADMITTED WITH FEBRILE NEUTROPENIA IN TIKURANBESSA SPECIALIZED TEACHING HOSPITAL, ADDIS ABABA, ETHIOPIA. Assefa S; Alemayehu T; Abebe W Ethiop Med J; 2017 Jan; 55(1):43-7. PubMed ID: 29148638 [TBL] [Abstract][Full Text] [Related]
16. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Cheng C; Gallagher EM; Yeh JY; Earl MA Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519 [TBL] [Abstract][Full Text] [Related]
17. Non-chemotherapy drug-induced neutropenia - an update. Andrès E; Mourot-Cottet R Expert Opin Drug Saf; 2017 Nov; 16(11):1235-1242. PubMed ID: 28879784 [TBL] [Abstract][Full Text] [Related]
18. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. Taplitz RA; Kennedy EB; Flowers CR J Oncol Pract; 2018 Apr; 14(4):250-255. PubMed ID: 29517953 [No Abstract] [Full Text] [Related]
19. Validation of risk stratification for children with febrile neutropenia in a pediatric oncology unit in India. Das A; Trehan A; Oberoi S; Bansal D Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27860223 [TBL] [Abstract][Full Text] [Related]